Key Highlights:
- Jubilant Biosys has opened a new discovery and preclinical research facility in Noida, significantly expanding its drug discovery capabilities and doubling its chemistry capacity for discovery and scale-up projects.
- The new hub complements the company’s existing Chemistry Research Innovation Centre (CRIC) and offers integrated services from discovery to scale-up. The 20,000 sq. ft. facility houses discovery labs and pilot plants with 15 reactors ranging from 20L to 250L, capable of handling synthesis volumes from hundreds of grams up to 25 kg.
- With more than 1,300 scientists across its operations in India and Europe, the company expects the expanded capacity to support growing demand for drug discovery partnerships, enabling faster project delivery and smoother transition to GMP manufacturing for IND filings and commercial development.
Implications:
Jubilant catapults into top-tier CRO/CDMO contender, snatching complex molecule work from Lonza/Capricor as India chemistry talent goes global.
Noida’s scale-up muscle slashes timelines for Big Pharma oncology/nephrology bets, crushing smaller players dependent on overseas capacity.
Source: Expresspharma | Image: Jubilant Biosys

No Comment! Be the first one.